Massive study digs into Real-World data to compare diabetes drugs for heart safety
NCT ID NCT07096063
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study looked at health records from over 887,000 people with type 2 diabetes and overweight to compare two drugs—tirzepatide and semaglutide—for preventing heart attacks, strokes, or death. The goal was not to test a new treatment but to see if analyzing real-world data can give reliable answers about which drug works better. No participants received any experimental treatment; researchers simply reviewed existing medical information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.